



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Invega™

Common Name: Paliperidone

PDL Category: Antipsychotic - Atypicals

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Abilify®	Non-Recommended
Risperdal®	Recommended
Seroquel®	Recommended

Summary

Indications and Usage: Schizophrenia

Mechanism of Action: Exact mechanism unknown; suspected to antagonize dopamine type 2 and serotonin type 2 receptors

Dosage Forms: Extended release tablets; 3, 6, and 9mg tablets

Recommended Dosage: Start by taking 6mg once daily

Common Adverse Drug Reactions: Fatigue, tachycardia, EPS, TD, elevated blood sugar levels

Contraindications: Patients with any hypersensitivity to any component of the compound

Manufacturer: Janssen, L.P.

Analysis: Invega™ is an extended release atypical antipsychotic that represents the first new drug in this class introduced since 2003. Use of a unique extended release mechanism allows for once-daily dosing and smooth plasma concentrations. The active ingredient of Invega™, paliperidone, is the primary active metabolite of the drug, Risperdal®. Early clinical trials suggest that side effects with Invega™, such as weight gain and EPS, are similar to placebo at six weeks due to the unique extended release delivery system. Other atypical antipsychotics are available on the Iowa Medicaid Recommended Drug List as recommended products that are also dosed once-a-day, and are more cost effective than Invega™.

IME Recommendation:

<input type="checkbox"/>	Preferred Drug	<input type="checkbox"/>	Recommended Drug
<input type="checkbox"/>	Non-Preferred Drug	<input checked="" type="checkbox"/>	Non-Recommended Drug
<input type="checkbox"/>	Preferred Drug with Conditions		